Header

UZH-Logo

Maintenance Infos

129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC): a multicenter single-arm phase II trial


Rothschild, S I; Zippelius, A; Prince, S Savic; Gonzalez, M; Weder, W; Xyrafas, A; Rusterholz, C; Pless, M (2016). 129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC): a multicenter single-arm phase II trial. Journal of Thoracic Oncology, 11(4 Suppl):S112.

Statistics

Citations

Dimensions.ai Metrics
6 citations in Web of Science®
5 citations in Scopus®
6 citations in Microsoft Academic
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Thoracic Surgery
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:April 2016
Deposited On:14 Feb 2017 15:25
Last Modified:02 Feb 2018 12:15
Publisher:Elsevier
ISSN:1556-0864
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1016/S1556-0864(16)30242-8
PubMed ID:27198270

Download

Full text not available from this repository.
View at publisher

Get full-text in a library